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The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia Leukemia (2017) 31, 2000-2005; doi:10.1038/leu. 2017.194 Recurrent chromosomal translocations are common initiation events and have provided important insights into the pathogenesis of AML, paving the way for the introduction of novel targeted therapies. However, clinical outcomes, in particular for patients with adverse cytogenetic features remain suboptimal. The chromosomal translocation t(7;11)(p15, p15), encoding the fusion protein NUP98-HOXA9 (NHA9), is a rare poor risk cytogenetic event in AML associated with a particularly poor prognosis. NHA9 brings the FG repeat-rich portion of the nucleoporin NUP98 upstream of the homeodomain and PBX heterodimerization domains of HOXA9, and acts as oncogenic transcription factor. 1 The pathogenic events underlying NHA9 remain poorly understood and herein, we aim to characterize the downstream mediators of this oncoprotein by determining the effects of the fusion using human cellular models.
We set out initially to compare the DNA binding sites of NHA9, HOXA9 and NUP98, by forced expression of these genes alone or the corresponding fusion gene by retroviral transduction of HEK93FT cell line and cord blood-isolated human hematopoietic progenitors (hHP). ChIP-seq analysis in the HEK293FT cellular model identified 4471 significant genomic regions (false discovery rate (FDR) o0.05) as target sites of the fusion protein, all located within -5/+ kb from the annotated transcription start site (TSS) (Supplementary Figure S1A ). They correspond to 1368 genes and 17 miRNAs ( Supplementary Table S1 ) of which 399 genes were also shown to be common targets of HOXA9 and 4 of NUP98 (Figure 1a , Supplementary Table S2 , Supplementary Figures S1C-D) (Supplementary methods) (Data deposited in GEO http://www. ncbi.nlm.nih.gov/geo/, accession number: GSE62587). Ingenuity pathway analysis of the NHA9 target series demonstrated a significant enrichment of pathways associated with tumorigenesis and leukemic differentiation (Supplementary Figure S1B) .
We next performed a detailed sequence analysis of the NHA9 binding sites using the MEME-ChIP algorithm and detected a significant overlap with binding of several HOX genes, including HOXA9, supporting a role for this homeodomain in the DNA binding of NHA9. Strikingly, NHA9 sites were enriched for a novel binding motif, CA/gTTT, that was present in one-third (n = 1421) of all NHA9 ChIP-seq regions ( Supplementary Table S3 ). This motif had not been previously associated with any known transcription Accepted article preview online 20 June 2017; advance online publication, 7 July 2017 factor and was not observed in wild type HOXA9 or NUP98 binding site experiments, suggesting that it is specific to NHA9 DNA binding. MEME-ChIP (SpaMO) was used to identify significant co-occurrences of other known DNA binding motifs with this novel NHA9 DNA binding motif. Binding motifs corresponding to 12 transcription factors, including other HOX family proteins such as HOXB7 or HOXD11, were found to be overrepresented within the region adjacent to CA/gTTT ( Supplementary Table S4 ), Letters to the Editor suggesting a possible functional cooperation with the fusion oncoprotein.
As the NHA9 target motifs are preferentially located more than 1 kb upstream/downstream of the TSS (Supplementary Figure  S1A ), we reasoned that NHA9 binding may coincide with particular enhancer elements. A similar distribution was also found for the identified HOXA9 target regions whereas NUP98 binding sites were mostly located within promoters, both in agreement with previous studies. 2, 3 We selected eight leukemia-related genes (MEIS1, HOXA9, PBX3, MET, BRAF, AF9, PTEN and NF1) identified as part of our NHA9 ChIP-seq experiments, for locus specific qChIP studies. A significant enrichment of H3K4me1, a chromatin mark that predicts poised and active enhancers, and RNA Polymerase II (PolII), which is consistent with the presence of the active form of the enhancers, 4,5 was shown within the NHA9 binding sites upstream of the eight genes (Figure 1b and Supplementary Figure S1E ). NHA9 expression levels were demonstrated to be comparable in our two cellular models (HEK293FT and hHP) (Supplementary Figure S1G ). Accordingly, we validated the ChIPseq results in the HEK293FT model (Supplementary Figure S1F ) using the same set of eight NHA9 target genes and also demonstrated binding of NHA9 to the eight enhancers in our second model system of NHA9-expressing hHP cells ( Figure 1c ), allowing us to confirm these findings in primary human hematopoiesis.
We next focused attention on the transcription factors MEIS1, HOXA9 and PBX3, as their overexpression is significantly related to adverse prognosis in AML (The Cancer Genome Atlas; 6 Supplementary Figure S1H ) and were previously reported to drive leukemogenesis through the formation of a transcriptional activator complex. 7 To test the importance of these three transcription factors in NHA9 pathogenesis, we completed reporter assays in HEK293FT cells by cloning the identified enhancers of MEIS1, HOXA9 or PBX3 into a luciferase reporter vector. A significant 1.6-2.8 fold induction in luciferase activity was observed when NHA9 was co-expressed for all three enhancers, indicating a direct induction of MEIS1, HOXA9 and PBX3 expression through the NHA9 interaction with their corresponding regulatory regions ( Figure 1d ) (Supplementary Methods). This observation was accompanied by upregulation of all three transcription factors and of three of their known target genes (MYB, MEF2C and FLT3) 7 in NHA9-expressing hHP cells (Figure 1e and Supplementary Figure S1I ). Gene Expression Profiling performed in three independent NHA9-expressing hHP clones and AMLs from five patients with t(7;11)(p15,p15), confirmed MEIS1-HOXA9-PBX3 overexpression and it was further validated by RT-qPCR analysis in three additional NHA9 primary samples (Supplementary Figure S2A ). These observations suggested that the NHA9expressing hHP cells can be sensitive to HXR9, a specific peptide inhibitor of HOXA9 and PBX3 interaction that leads to disruption of the MEIS1-HOXA9-PBX3 complex. 8 We tested this hypothesis by treating these cells with HXR9 that resulted in a selective decrease in their viability (Figure 1f and Supplementary Figure S2B-D) (Supplementary Methods) without affecting cell differentiation (data not shown), therefore confirming the relevance of these downstream mediators in driving the oncogenic activity of NHA9.
In order to explore other mechanisms driving NHA9 pathogenesis and to better understand its role in transcriptional regulation, we interrogated our ChIP-seq and gene expression profiling data, which revealed both activation and repression of gene expression . Genes were ranked based on the limma-moderated t statistic. After Kolmogorov-Smirnoff testing, those gene sets with FDR o0.25, a well-established cutoff for the identification of biologically relevant gene sets, were considered enriched (b) Analysis of NHA9 and p300/HDAC1 interactions by coimmunoprecipitation. HEK293FT cells were transfected with pMSCV-NUP98-HOXA9 or pMSCV-empty vectors. Forty-eight hours posttransfection, the immunoprecitpitation was performed using anti-p300 and anti-HDAC1 antibodies and the proteins were analyze by immunoblotting using anti-FLAG antibody. Endogenous GAPDH protein levels were used as a loading control. (c, d) qChIP fold enrichment of p300 and HDAC1 in the regulatory regions of four upregulated (c) and four downregulated (d) target genes of NHA9. The average of three experiments showed the binding, along with the fusion protein, of p300 and HDAC1 to the regulatory regions of the overexpressed and downregulated NHA9 target genes, respectively. (e) Analysis of the hHP-NHA9 response to HDAC inhibitors. Cells were exposed for 72 h to serial dilutions of panobinostat (LBH589) followed by the addition of WST-1 to assess cell viability. The average normalized optical density (OD) values are shown compared to vehicle. Statistical significance for relative enrichment and proliferation was determined at P o0.05 (*), Po0.01 (**) and Po0.001 (***), using a t-test with Bonferroni correction. N.S corresponds to non-significant comparisons. Error bars represent s.e.m.
induced by this fusion oncoprotein (Figure 2a ). The cooperation of MLL1 and CRM1 with NHA9 in the upregulation of some target genes has been shown recently by Xu et al., 9, 10 which was also supported by comparing NHA9 target genes identified in our ChIP-seq experiments with MLL1 and CRM1 targets. We found that 25% and 35% of NHA9 target genes were also in common with MLL1 and CRM1 target genes, respectively (Supplementary Figure S2E ). Notably, 151 target genes, including MEIS1 and HOXA9, were shared by all three proteins (NHA9, MLL1 and CRM1), suggesting a possible cooperation among these transcription factors in NHA9-driven leukemias. It has also been reported that NUP98, through its FG repeat domain, may interact with transcriptional activator p300 and repressor HDACs, 11 allowing us to postulate that transcriptional effects of NHA9 in enhancers could be mediated by these regulators. We first demonstrated NHA9 binding to both p300 and HDAC1 by co-immunoprecipitation experiments (Figure 2b ) (Supplementary Methods) and went on to examine their binding potential in a panel of eight regulatory regions of NHA9 target genes (four upregulated and four downregulated target genes) in the presence of the fusion protein by qChIP. These experiments demonstrated selective binding of p300 to the regulatory regions of the upregulated genes MEIS1, HOXA9, PBX3 and AFF3 (Figure 2c ), and of HDAC1 to the downregulated genes BIRC3, SMAD1, FILIP1L and PTEN (Figure 2d ). Altogether this data suggests that p300 and HDAC1 are selectively recruited by NHA9 at enhancer regions to modulate the expression of genes involved in leukemogenesis.
As the interaction of NHA9 with HDAC1/2 was validated by mass spectrometry analysis using the NHA9-expressing HEK293FT model (Proteomics data have been deposited on the ProteomeXchange Consortium via the PRIDE partner repository, data set identifier PXD001828) (Supplementary Methods), we had a molecular rationale for testing HDAC inhibitors (HDACi) in NHA9 AML. We assessed the sensitivity of the hHP-NHA9 model to the pan-HDACi LBH589 (Panobinostat) and observed a strong inhibitory effect that was significantly higher (IC50 hHP-NHA9 ≈4 nM) than its inhibitory effect in MLL-AF9expressing (IC50 hHP-MLL_AF9 ≈30 nM) or AML1-ETO-expressing (IC50 hHP-AML1_ETO ≈200 nM) hHP cells, 12, 13 where the efficacy of this component has been already established 14, 15 (Figure 2e ). Accordingly, treatment with low doses (4 nM) of LBH589 completely abrogated the ability of hHP-NHA9 cells to form colonies in the CFC assay (Supplementary Figure S2F ) and significantly induced apoptosis within 24 h (4 nM and 30 nM doses), whereas LBH589 had no effect at the same doses on the empty vector control hHP cells (Supplementary Figure S2G) . It has to be noted that LBH589 did not induce differentiation in NHA9-expressing cells as no significant changes in the number of CD11b positive cells were observed by flow cytometry analysis post treatment (data not shown). These observations are in accordance with a recent report suggesting the combination of COX or DNMT inhibitors with HDACi for treatment of NHA9 AML patients, 16 however in this study we identified the molecular rationale for HDACi therapy as well as a panel of target genes downstream of NHA9 that can be used as biomarkers for response to this treatment. Furthermore, our hHP-NH9A cellular model showed sensitivity to markedly lower concentrations of LBH589 (4 nM) than the recommended doses in preclinical studies and Multiple Myeloma Clinical Trials, 17, 18 indicating that LBH589 could be safely used as novel targeted therapy for the treatment of NH9A AML patients. However, the biological consequences of this therapy, as well as the best dosage-time relation for the translation into clinics need to be further investigated.
In summary, NHA9 deregulates the expression of key leukemic genes, including MEIS1-HOXA9-PBX3 complex, through the enhancer binding and the direct interaction of the fusion protein with HDAC and p300 transcriptional regulators. The oncogenic effects of NHA9 can be overcome by HDACi treatment, demonstrating a significant inhibitory effects against NHA9-driven leukemic cells and suggesting a novel approach to treatment of this high-risk group of patients. Philadelphia-negative neutrophilic leukemias-atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL), MDS/MPNu (myelodysplastic/myeloproliferative neoplasm, unclassifiable), and MPNu (myeloproliferative neoplasm, unclassifiable) -are rare hematologic neoplasms characterized by leukocytosis, a hypercellular bone marrow comprised predominantly of granulocytic cells, absence of the Philadelphia chromosome (t(9;22); BCR-ABL1), and absence of PDGFRA/B or FGFR1 gene rearrangements. Occasional cases of CNL 1 and MDS/MPNu, 2 as well as a majority of aCML cases, exhibit non-specific cytogenetic abnormalities 3 or the JAK2 V617F mutation, 4 revealing their clonal nature. The primary genetic basis of these leukemias was unknown until recent work by Maxson et al., 5 which highlighted mutations in CSF3R as key leukemogenic drivers in~60% of patients with aCML or CNL. Subsequent studies found CSF3R mutations in a majority of patients with CNL and only in a minority of patients with aCML, 6 with parallel studies of aCML revealing the presence of recurrent SETBP1 and ETNK1 mutations. 7, 8 Despite these discoveries, knowledge of the full genetic landscape of Philadelphia-negative neutrophilic leukemias remains incomplete. To identify and characterize additional mutations contributing to the pathogenesis of these malignancies, we performed whole exome sequencing (WES) on 116 Philadelphia-negative neutrophilic leukemia samples (Supplementary Materials and Methods).
We identified 4/116 samples harboring mutations in CCND2, the gene encoding the cell cycle regulator cyclin D2. Of these four samples, one was pathologically confirmed as MPNu, while another was confirmed as MDS/MPNu ( Supplementary Table 1 ). Interestingly, all mutated samples harbored variants in codon 281, with three samples possessing a P281S variant and the other carrying a P281L variant ( Supplementary Table 1 ). These changes appeared to occur as heterozygous mutations and were present only in patients lacking CSF3R mutations, with one sample (13-00010) harboring a known pathogenic SETBP1 variant (I871T), and another (14-00247) possessing an SRSF2 P95H variant. Two out of four samples harbored a TET2 mutation (other observed mutations in Supplementary Table 2 ). All mutations with additional available DNA were confirmed by Sanger sequencing ( Supplementary  Figure 1) .
To determine the potential incidence of CCND2 mutations in other hematologic malignancies, we interrogated cohorts of patients with AML (n = 239), BCR-ABL1-positive CML (CML; n = 44), chronic myelomonocytic leukemia (CMML; n = 24), B-cell acute lymphoblastic leukemia (B-ALL; n = 49), or T-ALL (n = 7) by whole exome sequencing for the presence of variants in CCND2 (Supplementary Table 2 ). We identified three AML patients harboring the same CCND2 variants (two P281S; one P281L), all confirmed as somatic ( Supplementary Table 3 ). These findings are consistent with two recent reports of similar CCND2 mutations in AML. 9, 10 No mutations in CCND2 were detected in patients with CML, CMML, B-ALL or T-ALL (Supplementary Table 2 ). Taken together, these results suggest the presence of CCND2 mutations may unify a small but recurrent and selective subset of patients with the molecularly heterogeneous myeloid malignancies of Philadelphia-negative neutrophilic leukemias and AML.
Previous work examining a missense variant in CCND2 (T280A), just one amino acid upstream of P281, demonstrated the variant to confer resistance to degradation. 11 To assess whether the nearby variants identified in our patient cohort resulted in similar protein accumulation, NIH-3T3 cell lines stably overexpressing either empty vector, wild-type CCND2, or mutant CCND2 were treated with cycloheximide to block protein translation, and protein extracts from cells were analyzed by Western blotting (Figure 1a ). While a rapid reduction in cyclin D2 protein was observed in cells overexpressing wild-type cyclin D2, this was not observed in cells overexpressing the mutant constructs. Therefore, CCND2 P281 variants result in the accumulation of degradationresistant cyclin D2.
Interestingly, the CCND2 T280A variant is also associated with constitutively nuclear localization of the protein. 11 Because of the proximity of the CCND2 P281 variants to the previously reported T280A variant, we hypothesized that CCND2 P281 variants would be constitutively nuclear in their localization. While overexpressed wild-type CCND2 exhibited predominantly nuclear localization during G 1 phase of the cell cycle and cytoplasmic staining during S phase, CCND2 P281 variant protein remained predominantly nuclear in its localization regardless of cell cycle phase (Figure 1b ). Quantification of mean pixel density in the nucleus confirmed statistical significance of this difference (P o0.0001; Figure 1c ).
Variants in cyclin D1 have been reported at analogous residues to P281S and P281L of cyclin D2, exhibiting predominantly nuclear localization and oncogenic properties. 12 We therefore assessed the transformative capacity of CCND2 P281 variants by generating Ba/F3 cell lines stably overexpressing either wild-type CCND2, CCND2 P281S or CCND2 P281L and removing IL-3 from their growth medium to assess for growth factor independence. As shown in Figure 2a , neither wild-type nor mutant CCND2 transformed Ba/F3 cells to IL-3-independent growth. However, Accepted article preview online 20 June 2017; advance online publication, 11 July 2017
